PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 144 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $315,227 | +66.8% | 11,413 | -49.1% | 0.01% | +14.3% |
| Q3 2022 | $189,000 | -18.5% | 22,421 | +128.9% | 0.01% | -36.4% |
| Q1 2022 | $232,000 | -15.0% | 9,795 | -6.9% | 0.01% | -56.0% |
| Q1 2021 | $273,000 | -25.0% | 10,522 | -41.8% | 0.02% | -35.9% |
| Q4 2020 | $364,000 | +92.6% | 18,074 | +68.8% | 0.04% | +200.0% |
| Q2 2020 | $189,000 | +30.3% | 10,707 | -47.7% | 0.01% | +18.2% |
| Q1 2020 | $145,000 | +17.9% | 20,481 | +11.8% | 0.01% | +37.5% |
| Q4 2018 | $123,000 | -59.5% | 18,317 | -38.1% | 0.01% | -65.2% |
| Q3 2018 | $304,000 | +57.5% | 29,580 | +31.4% | 0.02% | +76.9% |
| Q1 2018 | $193,000 | -45.8% | 22,506 | +31.6% | 0.01% | -66.7% |
| Q4 2017 | $356,000 | – | 17,106 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $26,721 | 7.77% |
| Bain Capital Life Sciences Investors, LLC | 2,364,410 | $25,796 | 2.88% |
| Sio Capital Management, LLC | 434,635 | $4,741,868 | 1.75% |
| Tri Locum Partners LP | 199,500 | $2,177,000 | 0.88% |
| Kynam Capital Management, LP | 520,922 | $5,683,259 | 0.87% |
| RTW INVESTMENTS, LP | 3,591,986 | $39,188,567 | 0.80% |
| Madison Avenue Partners, LP | 406,593 | $4,435,930 | 0.79% |
| Deep Track Capital, LP | 871,493 | $9,507,989 | 0.40% |
| Soleus Capital Management, L.P. | 236,000 | $2,574,760 | 0.37% |
| BRAIDWELL LP | 927,800 | $10,122,298 | 0.34% |